Advertisement
U.S. markets closed

Haemonetics Corporation (HAE)

NYSE - NYSE Delayed Price. Currency in USD
75.79+0.97 (+1.30%)
At close: 04:00PM EDT
76.83 +1.04 (+1.37%)
After hours: 07:47PM EDT

Haemonetics Corporation

125 Summer Street
Boston, MA 02110
United States
781 848 7100
https://www.haemonetics.com

Sector(s)Healthcare
IndustryMedical Instruments & Supplies
Full Time Employees3,034

Key Executives

NameTitlePayExercisedYear Born
Mr. Christopher A. SimonCEO, President & Director3.26MN/A1964
Mr. James C. D'Arecca CPACFO, Executive VP & Financial Officer1.8MN/A1971
Ms. Anila LingamneniExecutive VP & CTO1.09MN/A1968
Ms. Michelle L. BasilExecutive VP, General Counsel & Secretary1.26M1.34M1972
Mr. Josep Lluis LlorensExecutive Vice President of Global Manufacturing & Supply Chain1.11M79.93k1962
Ms. Farris Maryanne MaunsellVP, Chief Accounting Officer & Principal Accounting OfficerN/AN/A1975
Ms. Olga GuyetteSenior Director of Investor RelationsN/AN/AN/A
Mr. Rajeev VarmaSenior Vice President of Strategy & Corporate DevelopmentN/AN/AN/A
Ms. Laurie A. MillerSenior VP & Chief Human Resources OfficerN/AN/A1973
Dr. Jan Hartmann M.D.Senior VP & Chief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Corporate Governance

Haemonetics Corporation’s ISS Governance QualityScore as of March 1, 2024 is 3. The pillar scores are Audit: 3; Board: 2; Shareholder Rights: 4; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.